Accordingly, this proteolytic sequence has been referred to as the “Amyloidogenic Pathway” and has led to the suggestion that abnormal BACE1 activity is responsible for the pathogenesis of AD and highlighted the potential of BACE1 as a promising target for drug development to counteract AD progression [16]. Here, BACE1 is linked to Alzheimer disease.